![Y-mAbs Therapeutics, Inc. logo](/logos/YMAB.webp)
Y-mAbs Therapeutics, Inc.
NASDAQ:YMAB
Overview | Financials
Company Name | Y-mAbs Therapeutics, Inc. |
Symbol | YMAB |
Currency | USD |
Price | 13.82 |
Market Cap | 615,954,636 |
Dividend Yield | 0% |
52-week-range | 4.69 - 20.9 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Thomas Gad |
Website | https://www.ymabs.com |
An error occurred while fetching data.
About Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD